Saudi pharma market crucial to country’s Vision 2030
![](/46/pdcnewsitem/07/99/73/Saudi-pharma-market-crucial-to-countrys-Vision-2030.jpg)
Plan in the kingdom is to raise the percentage of total pharmaceutical production to 40% from the current 20%.
The importance of Saudi Arabia’s pharmaceutical industry in the delivery of the country’s 2030 Vision was highlighted at CPHI Middle East & Africa.
During a presentation by Dr Faisal BinDail, Chairman of the National Committee for Pharmaceutical Industries, titled Delivering Saudi Arabia’s Vision 2030, a range of topics related to the pharmaceutical industry were discussed, including incentives for stimulating local manufacturing and the opportunities the emerging contract manufacturing sector present.
Dr BinDail said: “In the context of Saudi Arabia, pharma manufacturing holds an important position in achieving the Kingdom’s Vision 2030. The regulatory body, local industry players, global companies have realised the importance of this initiative and are working towards strengthening localised pharmaceutical manufacturing. Part of the transformation plan in the kingdom is to raise the percentage of total pharmaceutical production to 40% from the current 20%. The Government is supportive, local companies are gearing up and the regulatory body is encouraging, facilitating and providing incentives – thereby encouraging global companies to take advantage of this opportunity.
“Moreover, there is an enthusiasm among the local players to raise their standards and provide quality affordable medicines. Saudi Arabia is one of the few countries to adopt track and trace system to curb the menace of counterfeit.”
Saudi Arabia is the largest pharmaceutical market in the MENA region worth US$7.5 billion dollars and is expected to grow at a CAGR of around 5.5%.
“The market is dominated by branded products, as there is a preference for brands locally, but at the same time there is an opportunity for generics as well to expand. Around 20% of the pharma market is locally manufactured, while 80% is still imported from different countries, from the US, Europe, and different parts of the world, this is in brief how the pharmaceutical market in Saudi Arabia currently looks like,” added Dr BinDail.
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance